The FORCE study, sponsored by Arbor Research Collaborative for Health, addresses a significant unmet need in pediatric hepatology by evaluating the non-invasive FibroScan™ technology for monitoring liver fibrosis in children with chronic cholestatic liver diseases. Given the limitations of liver biopsy, this study could pave the way for broader adoption of non-invasive techniques in clinical practice, potentially leading to increased market demand for FibroScan™ devices. The pediatric liver disease market is growing, driven by rising incidences of conditions like biliary atresia and Alagille syndrome. Companies involved in non-invasive liver assessment technologies may find strategic opportunities for partnerships or acquisitions based on the outcomes of this study.